2001
DOI: 10.1089/027245701300060382
|View full text |Cite
|
Sign up to set email alerts
|

A Monoclonal Antibody Specific for Human Thymidine Kinase 1

Abstract: Previous research has shown that thymidine kinase 1 (TK1), a nucleotide salvage pathway enzyme, is an accurate prognostic and diagnostic tumor marker. However, the current radioisotope assay for TK1 is cumbersome and has hampered the clinical application of this diagnostic technique in cancer management. To overcome the problems of the current radioisotope assay, we have produced monoclonal antibodies (MAbs) using purified TK1 from Raji cell extract. Production and confirmation of their specificity was confirm… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
13
0
2

Year Published

2004
2004
2017
2017

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(15 citation statements)
references
References 42 publications
0
13
0
2
Order By: Relevance
“…A series of recent publications describe the production and use of antibodies against TK1 (23)(24)(25)(26)(27)(28)(29). The authors of these reports have reported several interesting results, but there are some fundamental differences and problems with immunology-based measurements of TK1.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…A series of recent publications describe the production and use of antibodies against TK1 (23)(24)(25)(26)(27)(28)(29). The authors of these reports have reported several interesting results, but there are some fundamental differences and problems with immunology-based measurements of TK1.…”
Section: Discussionmentioning
confidence: 99%
“…Although immunochemical methods have been reported (23)(24)(25)(26)(27)(28)(29), a highly sensitive but convenient approach for routine measurement of serum TK1 in hematologic malignancies has not been forthcoming. Furthermore, antibody-based assays would most probably provide different clinical information than would activitybased measurements (23 ).…”
Section: © 2004 American Association For Clinical Chemistrymentioning
confidence: 99%
“…: снижение уровня маркера со-ответствовало степени редукции опухолевой массы и от-ражало эффективность лечения, а возрастание -отсут-ствие клинически значимой химиочувствительности [28]. Подобные изменения уровня ТК-1 в мониторинге ОМЛ и ОЛЛ описаны и в ряде других исследований [29][30][31][32][33][34].…”
Section: тк-1 при лимфопролиферативных заболеванияхunclassified
“…Необходимо отметить, что сопоставление данных, полу-ченных разными авторами, затруднено из-за использова-ния ими принципиально разных методов выявления ТК-1, несмотря на то, что сравнение активности (радиоиммун-ный анализ) и концентрации ТК-1 (иммуноферментный метод) в СК больных ОЛЛ и здоровых лиц показало на-личие относительно высокой (но не абсолютной) корреля-ционной связи между этими показателями (коэффициент корреляции Пирсона -0,806) [30].…”
Section: тк-1 при лимфопролиферативных заболеванияхunclassified
“…Sera samples from both sample groups were measured using a radioassay as well as an immunoassay employing a TK1-specific monoclonal antibody (mAb) developed in our laboratory. 8 Following a natural logarithm transformation to normalize the distribution of these data, the Student's t-test and one-way ANOVA were performed. The increase in the mean serum TK1 levels between the non-cancer control individuals and the ALL patients was statistically significant (Po0.05).…”
mentioning
confidence: 99%